

Special Issue

Targeting Neuroinflammation: Strategies for Drug Design of Therapeutic Agents and Molecular Imaging Probes

Message from the Guest Editors

Neuroinflammation is a complex and dynamic process that arises in response to injury, infection, or neurodegenerative stimuli within the central nervous system (CNS). It is primarily mediated by glial cells, especially microglia and astrocytes, which, upon activation, release cytokines, chemokines, and other inflammatory mediators. While acute neuroinflammation can be protective, promoting tissue repair and pathogen clearance, its chronic activation is increasingly recognized as a key driver of neuronal dysfunction and degeneration in disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

This Special Issue focuses on advanced strategies for targeting neuroinflammation, with particular emphasis on molecular imaging probes. Contributions are invited on the design, development, and application of fluorescence-based probes, radiopharmaceutical agents, and other innovative imaging tools, such as nanoparticle- and carrier-based probes, for visualizing inflammatory processes in the nervous system. Emphasis is placed on multidisciplinary approaches that integrate medicinal chemistry, radiopharmaceutical chemistry, (radio)pharmacology, and imaging technologies.

Guest Editors

Dr. Imane Ghafir El Idrissi

Dr. Enza Lacivita

Dr. Cristina Bolzati

Deadline for manuscript submissions

31 December 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/276407

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)